Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) has a beta value of 1.05 and has seen 1.7 million shares traded in the recent trading session. The company, currently valued at $315.52M, closed the recent trade at $0.86 per share which meant it gained $0.07 on the day or 9.07% during that session. The LXRX stock price is -333.72% off its 52-week high price of $3.73 and 27.91% above the 52-week low of $0.62. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.3 million shares traded. The 3-month trading volume is 4.27 million shares.
The consensus among analysts is that Lexicon Pharmaceuticals Inc (LXRX) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.12.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Over the past 30 days, the shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) have changed 25.53%. Short interest in the company has seen 31.28 million shares shorted with days to cover at 6.85.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 85.67% from the levels at last check today. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the latest price level in today’s session is -597.67% off the targeted high while a plunge would see the stock gain -597.67% from the levels at last check today.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Figures show that Lexicon Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -48.50% over the past 6 months, with this year growth rate of 16.46%, compared to 16.90% for the industry. Revenue growth from the last financial year stood is estimated to be 824.52%.
6 analysts offering their estimates for the company have set an average revenue estimate of 6.48M for the current quarter. 3 have an estimated revenue figure of 3.05M for the next ending quarter. Year-ago sales stood 702k and 1.13M respectively for this quarter and the next, and analysts expect sales will grow by 822.99% for the current quarter and 824.52% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 6.80% over the past 5 years.
LXRX Dividends
Lexicon Pharmaceuticals Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
Insiders own 1.15% of the company shares, while shares held by institutions stand at 81.91% with a share float percentage of 82.86%. Investors are also buoyed by the number of investors in a company, with Lexicon Pharmaceuticals Inc having a total of 184.0 institutions that hold shares in the company. The top two institutional holders are ARTAL GROUP S.A. with over 175.1 million shares worth more than $294.17 million. As of 2024-06-30, ARTAL GROUP S.A. held 71.3555% of shares outstanding.
The other major institutional holder is FMR LLC, with the holding of over 38.69 million shares as of 2024-06-30. The firm’s total holdings are worth over $64.99 million and represent 15.7656% of shares outstanding.
